Reeves, H. (Helen)

Filtering

2021 - 20222

Settings

Author search.filters.isAuthorOfPublication.dfdd9dac-5212-4c32-8d62-7be626e9c4da

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association
    (2022) Salem, R. (Riad); Allaire, M. (Manon); Korenjak, M. (Marko); Bruix, J. (Jordi); Maravic, Z. (Zorana); Sangro, B. (Bruno); Reeves, H. (Helen); Manes, S. (Sarah); Sherman, M. (Morris)
    Hepatocellular carcinoma (HCC) is a major public health problem worldwide for which the inci-dence and mortality are similar, pointing to the lack of effective treatment options. Knowing the different issues involved in the management of HCC, from risk factors to screening and manage-ment, is essential to improve the prognosis and quality of life of affected individuals. This document summarises the current state of knowledge and the unmet needs for all the different stakeholders in the care of liver cancer, meaning patients, relatives, physicians, regulatory agencies and health authorities so that optimal care can be delivered to patients. The document was commissioned by the International Liver Cancer Association and was reviewed by senior members, including two ex -presidents of the Association. This document lays out the recommended approaches to the societal management of HCC based on the economic status of a given region.(c) 2022 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/ by/4.0/).
  • Thumbnail Image
    Assessing the impact of COVID-19 on liver cancer management (CERO-19)
    (Elsevier, 2021) Muñoz-Martínez, S. (Sergio); Sapena, V. (Victor); Forner, A. (Alejandro); Nault, J.C. (Jean-Charles); Sapisochin, G. (Gonzalo); Rimassa, L. (Lorenza); Sangro, B. (Bruno); Bruix, J. (Jordi); Sanduzzi-Zamparelli, M. (Marco); Holówko, W. (Waclaw); Kassas, M. (Mohamed) El; Mocan, T. (Tudor); Merle, P. (Philippe); Hoogwater, F.J.H. (Frederik J.H.); Alqahtani, S.A. (Saleh A.); Reeves, H. (Helen); Pinato, D.J. (David J.); Giorgakis, E. (Emmanouil); Meyer, T. (Tim); Villadsen, G.E. (Gerda Elisabeth); Wege, H. (Henning); Salati, M. (Massimiliano); Mínguez, B. (Beatriz); Di-Costanzo, G.G. (Giovan Giuseppe); Roderburg, C. (Christoph); Tacke, F. (Frank); María Varela; Galle, P.R. (Peter R.); Alvares-da-Silva, M.R. (Mario Reis); Argemí, J. (Josepmaria)
    The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.